Proteomic screening revealed that TGF-β participates in the radioresistant phenotype, while addition of TGF-β-neutralizing antibodies repressed both EMT and CSC phenotypes, consequently sensitizing cancer cells to RT and decreasing tumorigenicity in vivo. This evidence concerns the gene TGFB1 and cancer.